Keryx Biopharmaceuticals appoints Mark Enyedy to its Board as Independent Director

– USA, MA – Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced the appointment of Mark J. Enyedy as an independent member of the company’s board of directors. Mr. Enyedy brings extensive biopharmaceutical leadership experience to the company. John Butler, chairman of the Keryx board of directors and president and chief executive officer of Akebia Therapeutics, Inc., has resigned from Keryx’s board. Current Keryx board member Michael Rogers has been appointed as chairman of the board. These changes are effective immediately.

“On behalf of the entire board, we look forward to Mike’s chairmanship and thank John for his contributions to our company,” said Greg Madison, president, chief executive officer and board member of Keryx Biopharmaceuticals. “We are thrilled to have Mark join our board. His experience building leading biopharmaceutical organizations will be invaluable to Keryx as we work to pursue our vision of building a leading multi-product company focused on kidney disease.”

“Keryx has a unique opportunity, as it prepares for the potential launch of an additional indication for Auryxia, to help more than one million adults with chronic kidney disease in the United States manage two complications of this illness,” said Mr. Enyedy. “Auryxia has all of the characteristics of a foundational medicine from which Keryx can build a leading multi-product company focused on improving outcomes for people with kidney disease. I look forward to working with the Keryx team in realizing this vision.”

“It has been a pleasure to work with the Keryx team,” said Mr. Butler. “I am proud of our accomplishments during my time on the board and I look forward to following the company’s continued success.”

Mr. Enyedy has more than 25 years of combined general management, business development, and legal experience in the biotechnology industry across multiple therapeutic areas. He currently serves as president and chief executive officer of ImmunoGen, Inc., a position he has held since 2016. Prior to ImmunoGen, Mr. Enyedy served as executive vice president and head of corporate development for Shire plc leading the company’s strategy, merger and acquisitions, and corporate planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as chief executive officer of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, and president of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the board of directors of Fate Therapeutics.

Pursuant to the company’s October 2015 financing transaction with The Baupost Group, LLC., Mr. Enyedy replaces Mr. Butler as Baupost’s board appointee.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine, Auryxia (ferric citrate) tablets.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>